Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid …
T Badar, A Nanaa, E Atallah, RM Shallis… - Blood cancer …, 2024 - nature.com
TP53 is a tumor suppressor gene located on the short arm of chromosome 17 (p13), known
to be involved in multiple cellular processes and regulate cell proliferation by responding to …
to be involved in multiple cellular processes and regulate cell proliferation by responding to …
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response …
O Karrar, M Abdelmagid, M Rana… - American journal …, 2024 - pubmed.ncbi.nlm.nih.gov
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in
newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and …
newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and …
[HTML][HTML] Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis
J Zhu, J Fan, T Xie, H Zhao, R Lu, Y Zhang, Y Li… - Frontiers in …, 2024 - frontiersin.org
Objective To compare the efficacy and safety of venetoclax (VEN) in combination with
chemotherapy (chemo) versus chemo alone in the treatment of acute myeloid leukemia …
chemotherapy (chemo) versus chemo alone in the treatment of acute myeloid leukemia …
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in
patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML …
patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML …
CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implications
F Zhang, Z Shen, J Xie, J Zhang, Q Wu, R Jiang… - Blood Cancer …, 2024 - nature.com
The transcription factor CCAAT/enhancer-binding proteinalpha (CEBPA) is a critical
mediator of granulocytic differentiation. Mutations of the CEBPA gene (CEBPAmut) occur in …
mediator of granulocytic differentiation. Mutations of the CEBPA gene (CEBPAmut) occur in …
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
K Hemminki, F Zitricky, A Försti, M Kontro… - Blood cancer …, 2024 - nature.com
Dear Editor, Overall survival has developed well in hematological malignancies but among
the main entities, 5-year survival in acute myeloid leukemia (AML) has remained the lowest …
the main entities, 5-year survival in acute myeloid leukemia (AML) has remained the lowest …
Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study
N Miyashita, M Onozawa… - British journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based
therapy in the real world: Hokkaido Leukemia Net Study Novel stratification for newly …
therapy in the real world: Hokkaido Leukemia Net Study Novel stratification for newly …
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
S Garciaz, PY Dumas, S Bertoli… - American Journal of …, 2024 - Wiley Online Library
Venetoclax‐azacitidine is the standard of treatment for unfit acute myeloid leukemia patients.
In the VIALE‐A study, treatment was given until progression but there are no data on its …
In the VIALE‐A study, treatment was given until progression but there are no data on its …
Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study
CL Wan, YH Huang, SM Huang, YL Xu, KW Tan… - Leukemia Research, 2024 - Elsevier
RUNX1 is one of the recurrent mutated genes in newly diagnosed acute myeloid leukemia
(AML). Although historically recognized as a provisional distinct entity, the AML subtype with …
(AML). Although historically recognized as a provisional distinct entity, the AML subtype with …
维奈克拉联合方案一线治疗新诊断急性髓系白血病的单中心真实世界研究
吴迪， 陈智超， 黎纬明 - 临床血液学杂志, 2024 - lcxy.whuhzzs.com
目的靶向药物BCL-2 抑制剂维奈克拉(venetoclax, VEN) 的出现革新了急性髓系白血病(acute
myeloid leukemia, AML) 的治疗格局, 尤其是对于老年或不适合强化疗的患者 …
myeloid leukemia, AML) 的治疗格局, 尤其是对于老年或不适合强化疗的患者 …